Table 3

Basic data and 2 × 2 comparisons to detect the strongest human leukocyte antigen association of the risk factorsa
A*02 B*51 BD patients Controls
+ + 72 29
+ 76 112
+ 45 11
73 161
A*24 B*51
+ + 26 6
+ 36 30
+ 91 34
119 237
B*57 B*51
+ + 8 0
+ 24 11
+ 111 40
131 262
Factor 1-B*51 A*02  A*24  B*57
Pc OR Pc OR Pc OR
Test 1 >0.05 0.62 >0.05 1.54 >0.05 6.17
Test 2 >0.05 1.49 0.008 2.38 <0.0006 4.25
Test 3 <0.0006 5.40 <0.0006 8.10 0.0012 33.9
Test 4 <0.0006 0.17 >0.05 0.45 >0.05 0.77

aBD, Behçet’s disease; HLA, human leukocyte antigen; odds ratio; Pc, corrected value of P. Test 1: ++ vs. –+ was performed to determine whether the HLA proposed factor was associated in B*51 positives. Test 2: +- vs. –– was designed to determine whether the HLA proposed factor was associated in B*51 negatives. Test 3: ++ vs. –– was conducted to determine the combined association between the HLA proposed factor and HLA-B*51. Test 4: +- vs. –+ was done to determine whether the associations between the HLA proposed factor and HLA-B*51 were different. Pc was calculated from the different 2 × 2 tables using Fisher’s exact test and corrected by multiplying by 6 (see [23]). Each comparison included B*51 and other HLA risk factors associated with the disease or suggestive of an association with the disease.

Montes-Cano et al.

Montes-Cano et al. Arthritis Research & Therapy 2013 15:R145   doi:10.1186/ar4328

Open Data